

# Burden of cardiovascular disease among elderly: based on the Global Burden of Disease Study 2019

Chunrun Qu<sup>1,2,3,†</sup>, Sheng Liao<sup>1,2,3,†</sup>, Jingdan Zhang<sup>3</sup>, Hui Cao<sup>4</sup>, Hao Zhang<sup>1,5</sup>, Nan Zhang<sup>6</sup>, Luzhe Yan<sup>3</sup>, Gaoyuan Cui<sup>3</sup>, Peng Luo<sup>1,7,\*</sup>, Qingwei Zhang<sup>8,\*</sup> and Quan Cheng<sup>1,2,\*</sup>

<sup>1</sup>Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China; <sup>2</sup>National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China; <sup>3</sup>XiangYa School of Medicine, Central South University, Changsha, Hunan, China; <sup>4</sup>Department of Psychiatry, Brain Hospital of Hunan Province (The Second People's Hospital of Hunan Province), Changsha, Hunan, China; <sup>5</sup>Department of Neurosurgery, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China; <sup>6</sup>College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, Hubei, China; <sup>7</sup>Department of Oncology, Zhujiajiao Hospital, Southern Medical University, Guangzhou, China; and <sup>8</sup>Division of Gastroenterology and Hepatology, NHC Key Laboratory of Digestive Diseases, Shanghai Institute of Digestive Disease, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

Received 30 March 2023; revised 29 May 2023; accepted 8 June 2023; online publish-ahead-of-print 9 June 2023

## Background

The burden of elderly cardiovascular disease (CVD) has received increasing attention with population ageing worldwide.

## Aims

We reported on the global CVD burden in elderly individuals over 70, 1990–2019.


## Methods and results

Based on the Global Burden of Disease Study 2019, elderly CVD burden data were analysed. Temporal burden trends were analysed with the joinpoint model. The slope index and concentration index were used to evaluate health inequality. From 1990 to 2019, the global elderly CVD incidence, prevalence, death, and disability-adjusted life year rates generally decreased. However, the current burden remains high. The rapid growth in burden in parts of sub-Saharan Africa and Asia is a cause for concern. Countries with a higher socio-demographic index (SDI) have generally seen a greater decrease in burden, while countries with a lower SDI have generally experienced increases or smaller declines in burden. Health inequality analysis confirmed that the burden was gradually concentrating towards countries with a low SDI. Among the different CVDs, ischaemic heart disease causes the greatest burden in elderly individuals. Most CVD burdens increase with age, but stroke and peripheral vascular disease show markedly different distributional characteristics. In addition, the burden of hypertensive heart disease shows an unusual shift towards high-SDI countries. High systolic blood pressure was consistently the leading risk factor for CVD among elderly individuals.

## Conclusion

The burden of CVD in older people remains severe and generally tends to shift to lower-SDI countries. Policymakers need to take targeted measures to reduce its harm.

## Graphical Abstract



## Keywords

Cardiovascular disease • Elder • Disease burden • Health inequality • Epidemiology

† The first two authors contributed equally to this work.

\* Corresponding author. Tel: +86-731-89753739, Fax: +86-731-84327401, Email: [chengquan@csu.edu.cn](mailto:chengquan@csu.edu.cn), [zhangqingweif@hotmail.com](mailto:zhangqingweif@hotmail.com), [luopeng@smu.edu.cn](mailto:luopeng@smu.edu.cn)

© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<https://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

## Key learning points

What is already known

- As ageing increases, the burden of cardiovascular disease in older people is a growing concern.

What this study adds

- The burden of cardiovascular disease in older people is generally shifting towards lower socio-economic countries, which are likely to face more serious challenges in the future.
- The burden of most types of cardiovascular disease increases with age, but the burden of stroke and peripheral vascular disease show markedly different distributional characteristics.

## Introduction

Cardiovascular disease (CVD) is the leading cause of global mortality and a significant contributor to poor quality of life.<sup>1</sup> In 2017, there were >17 million deaths from CVD, almost twice as many as from cancer.<sup>2</sup> In Europe, >60 million potential years of life are lost due to CVD annually.<sup>3</sup> For the past 30 years, the burden of CVD in high-income regions has decreased in general, whereas the burden is still heavy in low-income regions because of the differences between lifestyle, environment, education, and so on.<sup>2,4</sup> For example, ~75% of deaths from stroke and >80% of deaths from ischaemic heart disease occur in low- and middle-income countries.<sup>5,6</sup>

Age is a separate and unavoidable risk factor that reduces the cardiovascular system's ability to perform at its best.<sup>7</sup> According to the American Heart Association on Heart Disease and Stroke Statistics in 2019, the incidence of CVDs was typically 35–40% in people between the ages of 40 and 60, patients between the ages of 60 and 80 had an average incidence of 77–80%, and patients over the age of 80 had an incidence of over 85%.<sup>7,8</sup> During the last 200 years, average human life expectancy has doubled in most developed countries, and it is forecast that nearly one-fifth of the population in the world will be aged 65 or older by 2030.<sup>9,10</sup> In fact, ageing problems have become prominent worldwide, and the burden of CVD is currently falling mainly on elderly individuals.<sup>10</sup>

Globally, life expectancy at birth has recently increased to over 70 years in 2019.<sup>11</sup> The current growth of elderly adults over 70 is the fastest in many regions, such as Europe, the USA and Asia, and there is a lack of analysis of the global burden of CVD in those aged over 70.<sup>12</sup> Thus, it is urgent to identify the burden of elderly CVD, especially those over 70, providing additional information to local governments for alleviating this stress. The Global Burden of Disease (GBD) study 2019 provided four indicators for the disease burden, allowing for a more thorough and precise analysis. Using data from GBD 2019, we assessed the global, regional, and national burden of CVD in old age, its spatial and temporal distribution characteristics, its relationship to socioeconomic level, and its risk factors. First, we reported the elder CVD burden and its trend for the whole world, 21 regions and 204 countries and territories by gender. Second, we analysed the relationship between the CVD burden in older adults and socioeconomic level and assessed health inequalities. Afterwards, we reported the burden of different CVD subtypes by age and sex, with a specific assessment of the top four CVD subtypes that cause the most deaths. Finally, we analysed risk factors for CVD in older people from 1990 to 2019.

## Methods

### Data sources

GBD 2019 includes the latest estimation of descriptive epidemiological data on a total of 369 diseases and injuries for 204 countries and territories from 1990 to 2019, which was used to determine the worldwide burden of elderly CVD.<sup>13</sup> All countries and territories were divided into 21 regions and then into five categories based on the socio-demographic index (SDI).<sup>13</sup>

### Statistical analyses

In this study, we included the 10 most common global causes of CVD in elderly individuals.<sup>14</sup> People over the age of 70 were included in our analysis and divided into six age strata (70–74, 75–79, 80–84, 85–89, 90–94, and 95+). The burden of elderly CVD was analysed by sex, year, age, location, and cause. Incidence, prevalence, death, disability-adjusted life years (DALYs), and their rates were reported with 95% uncertainty intervals (UIs). Additionally, the annual percentage changes (APCs) and their 95% confidence intervals (CIs) were also calculated. R software (R Core Team, version 4.1.3, Vienna, Austria) and the Surveillance Research Program of the US National Cancer Institute's Joinpoint software (version 4.9.1) were used for analyses. The significance level used to evaluate the P-value was 0.05. The decomposition analyses demonstrated the contribution of age, epidemiological change, and population to the change in CVD burden between 1990 and 1991–2019. The slope index of inequality and the concentration index were used to calculate the degree of health inequities in the distribution of elderly CVD burden across countries (details in supplementary methods).

## Results

### Age and cardiovascular disease burden

Among all types of non-communicable diseases in 2019, CVD showed the greatest death rate and DALY rate in all age groups, especially in the 25–49, 50–69, and over 70 years groups, in which CVD ranked first (Supplementary online, Table S1). The CVD burdens were analysed among age groups 0–9, 10–24, 25–49, 50–69, and over 70 years. In 2019, patients aged over 70 years accounted for the largest incidence, prevalence, death, and DALY rates (Supplementary online, Figure S1). With the baseline of 1990, the burden change of CVD owing to ageing continued to increase from 1991 to 2019. From 1991 to 2019, the percentage of incidence and prevalence change attributed to ageing showed a general increase. Meanwhile, the proportion of

death changes and DALY changes due to ageing rose broadly between 1991 and 2019 (Supplementary online, *Figure S2*). Based on these findings, we focused on elderly individuals over 70.

## Global cardiovascular disease burden and its trend among elderly individuals

In 2019, 21 172 117 (95% UI, 19 279 481–23 193 109) new cases and 12 168 381 (10 817 275–12 969 353) deaths from elderly CVD were recorded, with 195 943 227 (185 037 643–207 466 433) prevalent cases and 162 402 754 (149 298 184–172 522 790) DALYs (*Table 1*). The global elderly CVD incidence, prevalence, death, and DALY rates have noticeably decreased since 1990. Specifically, the global incidence rate is continuing to decrease, with the fastest fall occurring between 1996 and 2000 (APC = −1.09%). However, the rate of this decline has slowed in recent years. The APC of incidence rate in 2017–19 was greater than the APC of incidence rate for any previous time period between 1990 and 2017 (2017–19 APC = −0.04). The prevalence rate decreased most of the time, but an increasing trend was observed in 2008–15 (APC = 0.07%). Since 1990, there has been a considerable decline in both the global death rate and the DALY rate, with the greatest reductions occurring between 2003 and 2007 (death rate: APC = −1.79%; DALY rate: APC = −1.95%) (*Figure 1*). For both sexes, from 1990 to 2019, decreasing trends were similar to the global trend. However, the rates of incidence, death, and DALY in males were consistently higher than those in females, whereas the prevalence rate in males was lower than that in females before 1997 (Supplementary online, *Figure S3*).

## Regional and national cardiovascular disease burden and its trend in elderly individuals

For region, in 2019, the incidence, death, and DALY rates of elderly CVD were highest in Central Asia, and prevalence rates were highest in Eastern Europe (Supplementary online, *Figure S4* and *Table S2*). Although the global burden has decreased, there were still some regions where the burden was on the rise and required special attention. Since 1990, in incidence and prevalence rates, the greatest decrease had been observed in Western Europe and the highest increase in East Asia. The second highest increase in incidence rate was in Central Asia, while the second highest increase in prevalence rate was in Western sub-Saharan Africa. Most regions have experienced a decline in death and DALY rates, with high-income Asia Pacific and Australasia, respectively, showing the largest declines. However, Central Asia experienced the largest increases, followed by southern sub-Saharan Africa (Supplementary online, *Figure S4* and *Table S2*).

At the national level, in 2019, the highest incidence, death, and DALY rates of elderly CVD were shown in Uzbekistan, while the highest prevalence rates were shown in Iran (Islamic Republic of) (*Figure 2* and Supplementary online, *Table S3*). Uzbekistan also had the greatest increase in incidence and DALY rates from 1990 to 2019. In addition, Tajikistan had the largest increase in mortality rate, while Guam had the largest increase in prevalence rate. The Republic of Korea showed the highest decline in incidence, prevalence, death, and DALY rates (Supplementary online, *Figure S5* and *Table S3*).

## Relationship between socioeconomic development status and cardiovascular disease burden among elderly individuals

Over this 30-year period, there were large differences between burden trends in countries with different SDIs. The burden has fallen the most in high-SDI countries, followed by high-middle-SDI countries. The decreasing trend in the burden is smaller in low-, low-middle-,

and middle-SDI countries, whose prevalence rate has even shown an increasing trend (*Table 1*).

To further validate the relationship between the burden of CVD in old age and socioeconomic level, we conducted an SDI-related health inequality analysis. The slope index indicated that SDI showed a significant positive correlation with the burden of CVD among elderly individuals in 1990. However, the burden showed a trend towards lower-SDI countries. In 2019, the positive correlation between incidence and prevalence rates and SDI was significantly weaker than that in 1990, while death and DALY rates even showed a significant negative correlation with SDI (Incidence 1990: 2338 to Incidence 2019: 470; Prevalence 1990: 18 361 to Prevalence 2019: 9758; Death 1990: 822 to Death 2019: −1010; DALY 1990: 3270 to DALY 2019: −20016) (*Figure 3*). The concentration index was also evidence of a gradual concentration of burden towards lower-SDI countries (Incidence 1990: 0.06 to Incidence 2019: −0.01; Prevalence 1990: 0.07 to Prevalence 2019: 0.02; Death 1990: 0.02 to Death 2019: −0.06; DALY 1990: −0.02 to DALY 2019: −0.09) (Supplementary online, *Figure S6*).

## Burdens of different cardiovascular diseases among elderly individuals

We further assessed the burden of different CVDs in elderly individuals. In 2019, except for the inaccessible incidence and prevalence of aortic aneurysm, ischaemic heart disease, the most common form of elderly CVD, was also the top cause of death and DALYs in elderly individuals with CVD of both sexes worldwide. Stroke, hypertensive heart disease, and atrial fibrillation and flutter were the other three most common reasons for death (Supplementary online, *Table S4*). From 1990 to 2019, the incidence, death, and DALY rates of rheumatic heart disease fell the most, and peripheral artery disease had the greatest decrease in prevalence. Meanwhile, endocarditis has had the most marked rise in incidence, death, and DALY rates.

In most CVDs, the burden increased with age, with the largest proportions of incidence, prevalence, death, and DALY rates occurring in those aged 95 years or older and the smallest in those aged 70–74 years. There was no significant difference between males and females in the rates at different ages. Interestingly, the distribution of certain disease burdens did not follow this pattern. In particular, the incidence rate of peripheral arterial disease even decreased with age after the age of 75–79. Furthermore, the prevalence and DALY rates for stroke in men tended to increase and then decrease with age (Supplementary online, *Figure S7*).

## Further analysis of the top four global cardiovascular diseases among elderly individuals

A more detailed assessment of the top four CVD burdens on elderly individuals worldwide was performed. Our ranking was based on the death rate brought about by different CVDs. For ischaemic heart disease in 2019, low-middle-SDI settings had the greatest rates of incidence and prevalence, while high-SDI settings had the lowest rates. Meanwhile, the lowest death and DALY rates also occurred in high-SDI settings. The greatest rates of DALY and death were found in high-middle-SDI settings. For stroke, high-SDI settings had the lowest rates of death and DALY. Among various age groups, the incidence and death rates increased with age, in which elders aged over 95 had the highest incidence and death rates, whereas elders aged 70–74 had the lowest. However, the rates did not increase simply with age in prevalence and DALY rates. In terms of subtypes, ischaemic stroke contributed to most death and DALY rates among all age groups and had the highest rates of incidence and prevalence (Supplementary

**Table I** Global burdens of elderly cardiovascular disease in 2019 and their annualized changes in rates from 1990 to 2019

Location	Sex	Incidence (95% UI)			Prevalence (95% UI)			Death (95% UI)			DALYs (95% UI)		
		Rate (per 100 000)	Count	Annualized rate of change (%)	Rate (per 100 000)	Count	Annualized rate of change (%)	Rate (per 100 000)	Count	Annualized rate of change (%)	Rate (per 100 000)	Count	Annualized rate of change (%)
Global	Both	21172117	456616	-0.17	195943227	4225875	-0.06	12168381	267433	-0.26	162402754	3502514	-0.3
	(19279481–23193109)	(415797–50022)	(-0.18 to -0.16)	(183037643–207466433)	(3990677–4474395)	(-0.07 to -0.05)	(10181725–12969353)	(233294–279738)	(-0.3 to -0.22)	(149298184–172522790)	(3219889–3720771)	(-0.34 to -0.26)	
Male	9467435	46427	-0.17	8624709	4239863	-0.05	5571366	273893	-0.25	7815159	384321	-0.29	
	(8571848–512021)	(421399–10415229)	(-0.18 to -0.15)	(81173320–91742076)	(3990549–4310118)	(-0.06 to -0.04)	(5091330–5950407)	(250294–292527)	(-0.3 to -0.2)	(78231447–83273683)	(357541–4093805)	(-0.34 to -0.24)	
Female	11704682	449729	-0.18	109698517	4214943	-0.07	6397015	253477	-0.27	84244596	3236928	-0.31	
	(10663374–12830464)	(409719–492985)	(-0.19 to -0.16)	(103401178–116224320)	(3972981–4465684)	(-0.08 to -0.06)	(5706263–718079)	(219252–276226)	(-0.32 to -0.21)	(75239349–90818198)	(289092–3489505)	(-0.36 to -0.26)	
High SDI	Both	5318583	414425	-0.33	56100053	4371324	-0.15	2297855	17949	-0.45	27551141	2146789	-0.5
	(489714–5789680)	(381638–451133)	(-0.35 to -0.32)	(53249405–58985405)	(4149201–456139)	(-0.17 to -0.14)	(1947277–2475656)	(191732–19293)	(-0.49 to -0.42)	(2494244–2947071)	(1893011–2296078)	(-0.52 to -0.48)	
Male	2364015	428179	-0.36	24386974	4453282	-0.16	1004298	181902	-0.46	1316232	238407	-0.53	
	(2171547–257582)	(393318–466136)	(-0.38 to -0.34)	(23321750–25873995)	(4224212–4686392)	(-0.17 to -0.14)	(8961538–1059269)	(162315–191815)	(-0.52 to -0.47)	(1208835–1389685)	(2193196–2512127)	(-0.55 to -0.51)	
Female	2254567	40404	-0.32	31513079	4309445	-0.15	1263557	178695	-0.42	1438819	1967685	-0.48	
	(2718841–3215480)	(371804–43972)	(-0.34 to -0.3)	(4087092–33193992)	(4339311)	(-0.17 to -0.14)	(1052354–1423053)	(14397–19464)	(-0.47 to -0.39)	(12230736–15631067)	(1672565–2137564)	(-0.52 to -0.46)	
High-middle SDI	Both	5911887	498851	-0.18	52744462	4433385	-0.05	374523	314804	-0.28	48908016	4042227	-0.34
	(5372276–6472308)	(451561–544043)	(-0.24 to -0.16)	(469775863–55845908)	(4183862–4694074)	(-0.06 to -0.04)	(3434075–402269)	(280996–33808)	(-0.33 to -0.24)	(4383203–5132096)	(368826–430264)	(-0.38 to -0.3)	
Male	2351246	478952	-0.18	20736330	4229536	-0.05	1574483	320724	-0.26	20559932	4396785	-0.33	
	(2127969–2584108)	(433476–52636)	(-0.24 to -0.16)	(39940008–22146208)	(41126128)	(-0.06 to -0.04)	(1425696–1699213)	(290244–361621)	(-0.35 to -0.23)	(4889522–5889522)	(4016169–4743169)	(-0.39 to -0.28)	
Female	3556841	509425	-0.18	31981033	4576591	-0.04	2170770	310644	-0.28	26330884	3796957	-0.35	
	(3330380–390026)	(462278–558107)	(-0.19 to -0.16)	(30135076–33815197)	(4312429–4839066)	(-0.05 to -0.03)	(188034–237982)	(269036–340533)	(-0.34 to -0.23)	(235647760–2887354)	(3372195–412846)	(-0.4 to -0.3)	
Middle SDI	Both	5808364	463058	-0.03	51114746	4078316	0.05	370613	296858	-0.13	51495523	4148599	-0.18
	(5263216–6368404)	(419939–508116)	(-0.05 to -0.01)	(47857690–4598628)	(3818443–4562286)	(0.04 to 0.06)	(3331750–402398)	(265832–321396)	(-0.22 to -0.05)	(47552064–502398)	(3794058–4469768)	(-0.26 to -0.11)	
Male	2676834	471016	-0.07	2278446	4009157	0.05	1827052	2109114	-0.09	26242617	4617657	-0.14	
	(2416010–2506956)	(425575–519198)	(-0.09 to -0.05)	(21284487–24442270)	(4301044)	(0.04 to 0.07)	(1640177–199878)	(307831–351741)	(-0.19 to 0.03)	(2367709–2887354)	(14174512–502284)	(-0.23 to 0.02)	
Female	3126809	456455	0.01	28330300	4135692	0.05	1893560	276424	-0.18	25753006	3759455	-0.23	
	(2331743–3427813)	(413381–50036)	(-0.01 to 0.03)	(26548103–4402369)	(3767345–466976)	(0.04 to 0.06)	(1640417–2109114)	(23947–307831)	(-0.28 to -0.06)	(3329553–4144042)	(348013–4721829)	(-0.32 to 0.13)	
Low-middle SDI	Both	3165772	463765	-0.01	27464263	4027736	0.04	1810208	265157	-0.09	26069655	3810238	-0.14
	(1427474–175572)	(472444–476698)	(-0.01 to 0.02)	(12388630–1485762)	(37614482–4032662)	(0.03 to 0.05)	(925754–25430)	(240428–307831)	(-0.17 to 0.0)	(348013–4144042)	(348013–4721829)	(-0.21 to -0.06)	
Male	1575907	504499	-0.01	3214741	4351589	0.05	884275	281402	-0.06	12505467	141721	-0.11	
	(1404093–175574)	(446823–578686)	(-0.02 to 0.01)	(12752625–16689438)	(40382251–451596)	(0.04 to 0.06)	(8004422–89623)	(25477–307831)	(-0.15 to 0.05)	(11744512–1416964)	(33744–37344)	(-0.19 to -0.01)	
Female	1585886	431578	0	13198145	37548482	0.04	253074	25430	-0.11	12659238	3544974	-0.16	
	(1427474–175572)	(472444–476698)	(-0.01 to 0.02)	(12388630–1485762)	(37614482–4032662)	(0.03 to 0.05)	(925754–25430)	(240428–307831)	(-0.17 to 0.0)	(348013–4144042)	(348013–4721829)	(-0.21 to -0.03)	

**Table I | Continued**

Location	Sex	Incidence (95% UI)			Prevalence (95% UI)			Death (95% UI)			DALYs (95% UI)		
		Rate (per 100 000)	Annualized rate of change (%)	Count	Rate (per 100 000)	Annualized rate of change (%)	Count	Rate (per 100 000)	Annualized rate of change (%)	Count	Rate (per 100 000)	Annualized rate of change (%)	Count
Low SDI	Both	962 744 (858 906– 1 073 321)	427 182 (381 108– 476 246)	−0.06 (−0.07 to −0.04)	839 595 (7 828 237– 9 014 812)	37 243 48 (34 734 91– 39 999 9)	0.03 (0.02–0.04)	588 70 (531 394– 640 608)	261 112 (235 37– 284 246)	867 4796 (7 934 750– 9 410 397)	38 491 2 (35 207 52– 41 755 16)	−0.08 (−0.18 to 0.01)	−0.13 (−0.22 to −0.05)
	Male	494 651 (438 538– 554 378)	460 668 (407 879– 515 62)	−0.1 (−0.11 to −0.08)	438 961 (408 6936– 440 1526)	40 830 45 (38 012 05– 47 323 82)	0.05 (0.04–0.06)	278 426 (251 452– 305 469)	258 96 (233 873– 284 113)	4 203 709 (3 817 735– 4 587 403)	3 909 814 (3 550 825– 4 266 633)	−0.1 (−0.19 to 0.04)	−0.15 (−0.23 to −0.02)
Female	Female	468 093 (419 285– 520 389)	397 18 (357 66– 4415 54)	−0.01 (−0.03 to 0.01)	403 634 (373 2433– 4 294 792)	32 971 13 (31 669 96– 36 441 62)	0.02 (0.01–0.03)	310 45 (272 302– 345 163)	263 075 (231 05– 292 873)	4 471 088 (3 978 731– 4 939 279)	3 793 75 (3 375 987– 4 191 013)	−0.06 (−0.22 to 0.12)	−0.11 (−0.25 to 0.05)

Abbreviations: UI, uncertainty interval; DALYs, disability-adjusted life years; SDI, sociodemographic index.

online, *Figure S8*). In 2019, for hypertensive heart disease, high-SDI settings presented the lowest prevalence and the lowest rates of death and DALY. The greatest death rate and DALY rate were observed in low-SDI settings. In 2019, the highest incidence and prevalence rates of atrial fibrillation and flutter were found in high-SDI settings, while low-SDI settings were the lowest. Meanwhile, the lowest death and DALY rates occurred in low-SDI settings, and the highest occurred in high-SDI settings. The 30-year trend in ischaemic heart disease, stroke, and atrial fibrillation and flutter burden was broadly consistent with the trend in overall CVD burden, all of which showed a gradual shift in burden towards lower-SDI countries. However, hypertensive heart disease showed unusual characteristics, with high- and high-middle-SDI countries accounting for a greater share of its burden in 2019 than in 1990. Detailed data on the top four causes are shown in Supplementary online, Tables S5–8.

## Changes in leading risk factors


High systolic blood pressure consistently accounted for the greatest proportion of elderly CVD deaths between 1990 and 2019, followed by dietary risks, which remained the top two causes of death in 1990 and 2019 (*Figure 4A*).

The leading risks were similar between males and females. For males and females, the leading risks in 2019 were high systolic blood pressure, dietary risks, high LDL cholesterol, and high fasting plasma glucose. Tobacco was the fifth risk factor for males, while it ranked eighth for females. Additionally, for the risk factors for death from CVD, the rank of air pollution was higher in females than in males. In terms of the top five risks, males had three metabolic risks and two behavioural risks, while females had three metabolic risks, one behavioural risk, and one environmental or occupational risk (*Figure 4B* and *C*).

## Discussion

### Principal findings

This study explored comprehensively the global burden and trend of CVD among elderly individuals over 70 and generated some new findings. From 1990 to 2019, the global incidence, prevalence, death, and DALY rates of CVD in older people all showed promising declines (*Table 1*). However, the current global burden of CVD among elderly individuals remains high, and the decline in incidence has slowed (*Table 1* and *Figure 1*). At the regional level, Central Asia and Eastern Europe had the greatest burden, and parts of sub-Saharan Africa and Asia experienced the sharpest increase in burden (Supplementary online, *Table S2* and *Figure S4*). As a representative of the high risk of CVD in older people in Central Asia, Uzbekistan had the largest incidence, death, and DALY rates and the largest increase in death and DALY rates of any country and territory, requiring special attention (Supplementary online, *Table S3*, *Figure 2*, and Supplementary online, *Figure S5*). Trends in burden changes varied across countries with different SDIs. High-SDI and high-middle-SDI countries generally experienced a significant decline in burden, while most of the lower-SDI countries experienced only a small decline or even a slight increase (*Table 1*). Further analysis of health inequalities suggested that the concentration of burden was shifting to low-SDI countries (*Figure 3*, Supplementary online, *Figure S6*). The burden of CVD increased with age in different 5-year age groups (Supplementary online, *Figure S7*). However, the burden due to different CVD subtypes showed different characteristics. The incidence rate of peripheral vascular disease decreased with age after the age of 75–79. The prevalence and DALY rates for stroke in males tended to increase and then decrease with age (Supplementary online, *Figure S7*). Among the different subtypes, ischaemic heart disease caused the greatest burden, while the trend towards increased incidence, death, and DALY rates was



**Figure 1** Global trends for incidence rate, prevalence rate, death rate, and DALY rate (per 100 000 population) of elderly cardiovascular disease from 1990 to 2019. (a) Incidence rate; (b) prevalence rate; (c) death rate; and (d) DALY rate. Abbreviation: DALY, disability-adjusted life year.


most pronounced in endocarditis (Supplementary online, *Table S4*). In addition, the burden of hypertensive heart disease in older people showed a trend towards countries with high SDI (Supplementary online, *Table S7*). Of the different risk factors, the one that had the greatest impact on CVD mortality in older people was high systolic blood pressure, followed by dietary factors (*Figure 4*). Our study provides a systematic analysis of the global burden caused by CVD among elderly individuals to help implement more effective and targeted measures to minimize harm.

## Comparison with other studies

To the best of our knowledge, this study provides the most recent and comprehensive analysis available on the burden of CVD among elderly individuals over 70 on a global, regional, and national level from 1990 to 2019. CVD remains the main cause of disease burden worldwide, and ageing is an important risk factor affecting cardiovascular homeostasis.<sup>14,15</sup> Consistent with previous studies, this analysis revealed a global decline in rates of death and DALY since 1990, which is attributable to recent more precise diagnoses and better therapies (*Table 1*).<sup>14</sup> The incidence and prevalence rates of

CVD in the elderly are also on the decline, and healthier lifestyles and better prevention strategies may be important reasons for this (*Table 1*).<sup>16,17</sup> However, the decline in incidence has slowed in recent years (*Figure 1*). Global warming, long-term air pollution exposure, etc. may be associated with the slowing of this trend.<sup>18,19</sup> Ageing is strongly associated with CVD burden, and it is forecast that approximately one-fifth of the global population will be over the age of 65 by 2030, with the prevalence of CVD increasing exponentially<sup>9</sup>; thus, there is still a huge challenge to elderly health and social development.

Although the global burden was declining, there were still some regions where the burden was trending upwards. Of the 21 regions, East Asia, Central Asia, and western sub-Saharan Africa have seen the sharpest increases in incidence and prevalence rates, while Central Asia and southern sub-Saharan Africa have seen non-negligible increases in death and DALY rates (Supplementary online, *Figure S4*, and *Table S2*). The incidence and prevalence rates of most CVDs increased with age (Supplementary online, *Figure S7*). The generally lower birth rates and longer life expectancy in East Asian countries have led to changes in age structure,<sup>20</sup> which may be the main reason for the increased incidence and prevalence burden in the region. From




**Figure 2** National incidence rate, prevalence rate, death rate, and DALY rate (per 100 000 population) of elderly cardiovascular disease for both sexes combined in 2019. (a) Incidence rate; (b) prevalence rate; (c) death rate; and (d) DALY rate. Notes: The raw data are from GBD2019, and possible zoning issues are not our focus. Abbreviations: DALY, disability-adjusted life year; GBD, Global Burden of Disease.

1990 to 2030, East Asia is also expected to have the largest worldwide increase in the proportion of people aged 65+ (from 12.9 to 18.1%).<sup>21</sup> The local area may face an even greater challenge of CVD in old age in the future. According to our study, dietary risk was an important risk factor for CVD in the elderly (Figure 4). The large increase in the risk of CVD among older people in sub-Saharan Africa may be strongly associated with the large amount of extra-regional trade experienced by the southern African Development Community. The main diet of the local population shifted from highly nutritious and fibrous staples to imported processed foods and sugary beverages, which often led to higher CVD incidence and death rates among the elderly.<sup>22–24</sup> The ‘collision’ epidemic of HIV and CVDs in ~2000 is also a possible cause of the rising local death burden.<sup>25</sup> The rapidly increasing burden in Central Asia may be related to local dietary habits.<sup>2</sup> Apart from the risk of diet, diabetes, hypertension, alcohol, tobacco, insufficient preventive care, and education also take part in the progressive burden of elderly CVD in Central Asia.<sup>26,27</sup> In addition, the break-up of the former Soviet Union is also a possible cause of this increase.<sup>28</sup>

Among the different countries and territories, as a prominent representative of Central Asian countries at high risk of CVD in older age, Uzbekistan has shown the largest increases in incidence and DALY rates over the past 30 years (Supplementary online, Figure S5 and Table S3). In 2019, Uzbekistan also had the highest rates of CVD incidence, death, and DALY rates in older age in the world (Figure 2, Supplementary online, Table S3). The shortage of healthcare resources, income inequality, limited drug affordability, and excessive use of alcohol and tobacco participated in the progress of burden of

CVD among elders in Uzbekistan.<sup>29</sup> However, current research on CVD among elderly individuals in Uzbekistan is inadequate, which is not conducive to improving this situation. Interestingly, in terms of countries and territories, the Republic of Korea showed the largest decrease in rates of incidence, prevalence, death, and DALY from 1990 to 2019 (Supplementary online, Figure S5 and Table S3). The range of measures taken by local authorities to reduce the burden of CVD in old age, such as establishing legal frameworks and new regional cardio-cerebrovascular centres, are worthy of study by policymakers in other countries.<sup>30</sup>

Although the burden has generally fallen, the downwards trend varies between SDI regions. Burden tended to fall more in high SDI areas, while it often fell slightly or even rose in low SDI areas (Table 1). The SDI-related health inequality analysis confirmed that the burden of CVD in older people was gradually shifting to countries with lower SDI (Figure 3, Supplementary online, Figure S6). The most plausible explanation for the greater decline in high-SDI countries may be better control of risk factors such as hypertension and obesity in older people and higher budgets for CVD prevention and treatment.<sup>31,32</sup> Low-SDI countries, on the other hand, tend to have lower budgets for CVD screening, prevention and treatment, and relatively inadequate education and skills of health workers.<sup>33</sup> Although treatment modalities for CVD are improving, the effect of this improvement may be uneven across countries. The low availability and accessibility of drugs in low-SDI countries is a major barrier to the use of and adherence to essential CVD drugs.<sup>34</sup> In addition, unlike developed countries, the older population in less developed countries is growing significantly slower than younger people in terms of access to health services, and



**Figure 3** SDI-related health inequality regression lines for the burden of cardiovascular disease in older people in 1990 and 2019. (a) Incidence rate; (b) Prevalence rate; (c) Death rate; and (d) DALY rate. Abbreviations: SDI, socio-demographic index; DALY, disability-adjusted life year.

the link between age discrimination and the health of older people appears to be stronger.<sup>35,36</sup> It is expected that in the future, countries with low socioeconomic levels will face a greater challenge of CVD in old age, which requires urgent attention.

We found that the burden of overall CVD among older people increases with age (Supplementary online, Figure S7), which has been verified in previous studies.<sup>37</sup> However, the distribution of burden for certain CVD subtypes did not follow this profile. The incidence of peripheral vascular disease decreased with age from 75 to 79 years onwards (Supplementary online, Figure S7). An increase followed by a decrease with age was also observed in the prevalence and DALY rates of stroke in men (Supplementary online, Figure S7). Although the exact mechanisms still need to be further explored, this is a reminder of the need for increased attention to the burden of disease in specific age groups.

Of the different subtypes of CVD, ischaemic heart disease caused the greatest burden (Supplementary online, Table S4). Its risk has been described in previous studies.<sup>38</sup> The most widespread increase in the burden of endocarditis in the elderly cannot be ignored (Supplementary online, Table S4), and the increasing risk of healthcare-associated infective endocarditis is a major reason for this.<sup>39,40</sup> It is

certainly necessary to develop more effective treatment and care for elderly patients with healthcare-associated infective endocarditis. In contrast to the overall CVD burden, the burden of atrial fibrillation and flutter quantified by all four indicators was unusually higher in countries with high SDI than in countries with low SDI (Supplementary online, Table S8). This suggests that high socioeconomic levels may be an important risk factor for atrial fibrillation and flutter. Genetic factors may also take part in this, with European ancestry associated with increased risk while both African and South Asian populations at lower risk.<sup>41–44</sup> In addition, unlike overall CVD, the burden of hypertensive heart disease exhibited a trend towards higher SDI areas (Supplementary online, Table S7). Although the exact causes need to be further explored, this is a reminder that targeted measures are needed in high-SDI countries to reduce the current huge burden of atrial fibrillation and flutter in older people and to solve the potentially huge future problem of hypertensive heart disease in older people.

In 2019, high systolic blood pressure was still the top risk factor for elderly CVD (Figure 4). Studies have shown the protective effect of blood pressure lowering on CVD.<sup>45,46</sup> Behavioural risk seems to be more important in men, such as tobacco (Figure 4).

**A Both sexes**

Leading risks 1990

Leading risks 2010

Mean annualized rate of change in number of death, 1990–2010 (%)

Mean annualized rate of change in rate of death, 1990–2010 (%)

Leading risks 2019

Mean annualized rate of change in number of death, 2010–2019 (%)

Mean annualized rate of change in rate of death, 2010–2019 (%)

1 High systolic blood pressure	1 High systolic blood pressure	-0.28	0.28	1 High systolic blood pressure	-0.16	0.09
2 Dietary risks	2 Dietary risks	-0.25	0.34	2 Dietary risks	-0.15	0.1
3 High LDL cholesterol	3 High fasting plasma glucose	-0.44	-0.1	3 High fasting plasma glucose	-0.18	0.05
4 Air pollution	4 High LDL cholesterol	-0.22	0.38	4 High LDL cholesterol	-0.17	0.07
5 High fasting plasma glucose	5 Air pollution	-0.28	0.28	5 Air pollution	-0.08	0.19
6 Tobacco	6 Tobacco	-0.2	0.43	6 High body-mass index	-0.21	0.02
7 High body-mass index	7 High body-mass index	-0.39	0.08	7 Tobacco	-0.08	0.19
8 Kidney dysfunction	8 Kidney dysfunction	-0.36	0.14	8 Kidney dysfunction	-0.18	0.06
9 Non-optimal temperature	9 Non-optimal temperature	-0.27	0.3	9 Non-optimal temperature	-0.12	0.13
10 Low physical activity	10 Other environmental risks	-0.46	-0.03	10 Other environmental risks	-0.19	0.05
11 Other environmental risks	11 Low physical activity	-0.32	0.21	11 Low physical activity	-0.19	0.05
12 Alcohol use	12 Alcohol use	-0.48	-0.7	12 Alcohol use	-0.18	0.06

**B Males**

1 High systolic blood pressure	1 High systolic blood pressure	-0.34	0.25	1 High systolic blood pressure	-0.17	0.09
2 Dietary risks	2 Dietary risks	-0.3	0.32	2 Dietary risks	-0.16	0.10
3 High LDL cholesterol	3 High fasting plasma glucose	-0.49	-0.04	3 High fasting plasma glucose	-0.2	0.06
4 Tobacco	4 High LDL cholesterol	-0.27	0.38	4 High LDL cholesterol	-0.19	0.07
5 Air pollution	5 Tobacco	-0.27	0.38	5 Tobacco	-0.09	0.19
6 High fasting plasma glucose	6 Air pollution	-0.34	0.24	6 Air pollution	-0.09	0.2
7 Kidney dysfunction	7 High body-mass index	-0.45	0.03	7 High body-mass index	-0.24	0
8 High body-mass index	8 Kidney dysfunction	-0.41	0.12	8 Kidney dysfunction	-0.19	0.06
9 Non-optimal temperature	9 Non-optimal temperature	-0.34	0.25	9 Non-optimal temperature	-0.14	0.13
10 Other environmental risks	10 Other environmental risks	-0.48	-0.02	10 Other environmental risks	-0.18	0.08
11 Low physical activity	11 Low physical activity	-0.37	0.19	11 Low physical activity	-0.21	0.04
12 Alcohol use	12 Alcohol use	-0.43	0.07	12 Alcohol use	-0.2	0.06

**C Females**

1 High systolic blood pressure	1 High systolic blood pressure	-0.24	0.3	1 High systolic blood pressure	-0.15	0.08
2 Dietary risks	2 Dietary risks	-0.2	0.38	2 Dietary risks	-0.14	0.1
3 High LDL cholesterol	3 High LDL cholesterol	-0.19	0.39	3 High LDL cholesterol	-0.16	0.07
4 Air pollution	4 High fasting plasma glucose	-0.4	0.02	4 High fasting plasma glucose	-0.17	0.05
5 High fasting plasma glucose	5 Air pollution	-0.23	0.32	5 Air pollution	-0.07	0.19
6 High body-mass index	6 High body-mass index	-0.35	0.11	6 High body-mass index	-0.19	0.04
7 Tobacco	7 Kidney dysfunction	-0.32	0.17	7 Kidney dysfunction	-0.17	0.05
8 Kidney dysfunction	8 Tobacco	-0.05	0.63	8 Tobacco	-0.06	0.2
9 Non-optimal temperature	9 Non-optimal temperature	-0.22	0.34	9 Non-optimal temperature	-0.11	0.13
10 Low physical activity	10 Low physical activity	-0.29	0.21	10 Low physical activity	-0.18	0.05
11 Other environmental risks	11 Other environmental risks	-0.43	-0.02	11 Other environmental risks	-0.2	0.02
12 Alcohol use	12 Alcohol use	-0.9	-0.83	12 Alcohol use	0	0.28

**Figure 4** Mean annualized rate of change in the number and rate of death in elderly cardiovascular disease due to various risk factors and their ranking change between sexes from 1990 to 2010 and 2010 to 2019. Notes: Solid lines indicate a rise, and dotted lines indicate a fall. Yellow for behavioural risks, blue for metabolic risks, and red for environmental/occupational risks.

## Strengths and limitations

To the best of our knowledge, this study provides the first comprehensive assessment of the global burden of CVD in old age and its spatial-temporal distribution characteristics through four indicators. We also provide an in-depth analysis of the relationship between burden and socioeconomic levels.

This work has some limitations. First, the burden on countries with low socioeconomic levels may be underestimated due to underdeveloped public health systems and unstable national situations. Second, the GBD study did not provide data on burden by ethnicity. However, ethnicity and genetic factors can greatly influence the distribution of CVD in older people in different countries and territories. Third, the most recent changes in CVD among elderly individuals cannot be captured owing to time lags in information reporting by national authorities in the GBD study. Fourth, the distribution of CVD burden in older people within a given country may vary considerably, for example, in the USA, which has a large geographical area. It is therefore necessary to assess the burden in different subnational regions, and

this will be done in further studies. Fifth, access to CVD diagnostic techniques may affect the accuracy of the estimated results. For example, electrocardiogram of atrial fibrillation—which can underestimate disease prevalence. Sixth, data on the incidence and prevalence of aortic aneurysms could not be obtained from the GBD, and further research is needed.

## Future directions

As the global population ages, CVD among the elderly is becoming an increasingly serious public health issue, warranting further investigation. The overall burden of CVD demonstrates a trend towards countries with lower socioeconomic levels, indicating that low-SDI countries may face a substantial CVD challenge in the future. Moreover, the actual burden in these countries might exceed the observed burden. Despite this, current research on CVD in the elderly remains predominantly focused on developed countries, highlighting an urgent need for additional studies in low-SDI countries. The increasing trend

of endocarditis burden in the elderly is far ahead of other CVD burden changes and needs more attention in the future. To fully understand the distributional characteristics of the burden of CVD in older people, more assessments should also be conducted on the burden in different ethnic and subnational regions.

## Conclusion

Our study offers an extensive evaluation of the global burden of CVD in older adults and its spatiotemporal distribution patterns. Despite a general decrease in burden, the impact of CVD in the elderly remains substantial. The burden trends vary across SDI regions and are progressively shifting towards lower SDI regions. Ischaemic heart disease poses the most significant burden among all CVDs, while the pervasive upwards trend in endocarditis burden is concerning. The distribution characteristics of different CVDs are distinct. The insights provided by our research will assist policymakers in devising targeted strategies to effectively mitigate the burden of CVD in older adults.

## Supplementary material

Supplementary material is available at [European Heart Journal—Quality of Care and Clinical Outcomes](#) online.

## Acknowledgement

We highly appreciate the work of the GBD Study 2019 collaborators for providing the most comprehensive analysis of diseases on a global scale.

## Funding

No funding.

**Conflict of interest:** None declared.

## Author Contribution

All authors contributed to the study conception and design. Material preparation and data collection were performed by C.Q. and S.L. Statistical analyses were performed by C.Q. and S.L. The first draft of the manuscript was written by C.Q. and S.L. J.Z., H.C., H.Z., N.Z., L.Y., and G.C. reviewed and made significant revisions to the manuscript. P.L., Q.Z., and Q.C. guided the preparation of this manuscript. All authors read and approved the final manuscript.

## Data availability

All data are accessible through the GBD query tool (<http://www.healthdata.org/gbd/2019>).

## Ethics approval and consent to participate

For the Global Burden of Disease study, a waiver of informed consent was reviewed and approved by the Institutional Review Board of the University of Washington. All the information about ethical standards is available through the official website (<http://www.healthdata.org/gbd/2019>). Informed patient consent is not required.

## References

- Mensah GA, Roth GA, Fuster V. The global burden of cardiovascular diseases and risk factors: 2020 and beyond. *J Am Coll Cardiol* 2019; **74**:2529–2532. doi: [10.1016/j.jacc.2019.10.009](https://doi.org/10.1016/j.jacc.2019.10.009)
- Dong C, Bu X, Liu J, Wei L, Ma A, Wang T. Cardiovascular disease burden attributable to dietary risk factors from 1990 to 2019: a systematic analysis of the Global Burden of Disease study. *Nutr Metab Cardiovasc Dis* 2022; **32**:897–907. doi: [10.1016/j.numecd.2021.11.012](https://doi.org/10.1016/j.numecd.2021.11.012)
- Townsend N, Kazakiewicz D, Lucy Wright F, Timmis A, Hucleci R, Torbica A et al. Epidemiology of cardiovascular disease in Europe. *Nat Rev Cardiol* 2022; **19**:133–143. doi: [10.1038/s41569-021-00607-3](https://doi.org/10.1038/s41569-021-00607-3)
- Rosengren A, Smyth A, Rangarajan S, Ramasundarahettige C, Bangdiwala SI, Al-Habib KF et al. Socioeconomic status and risk of cardiovascular disease in 20 low-income, middle-income, and high-income countries: the Prospective Urban Rural Epidemiologic (PURE) study. *Lancet Glob Health* 2019; **7**:e748–e760. doi: [10.1016/s2214-109x\(19\)30045-2](https://doi.org/10.1016/s2214-109x(19)30045-2)
- Gupta R, Yusuf S. Challenges in management and prevention of ischemic heart disease in low socioeconomic status people in LLMICs. *BMC Med* 2019; **17**:209. doi: [10.1186/s12916-019-1454-y](https://doi.org/10.1186/s12916-019-1454-y)
- Pandian JD, Gall SL, Kate MP, Silva GS, Akinyemi RO, Ovbiagiele BI et al. Prevention of stroke: a global perspective. *Lancet* 2018; **392**:1269–1278. doi: [10.1016/s0140-6736\(18\)31269-8](https://doi.org/10.1016/s0140-6736(18)31269-8)
- Ciumărnean L, Milaciu MV, Negrean V, Orășan OH, Vesa SC, Sălăgean O et al. Cardiovascular risk factors and physical activity for the prevention of cardiovascular diseases in the elderly. *Int J Environ Public Health* 2021; **19**:207. doi: [10.3390/ijerph19010207](https://doi.org/10.3390/ijerph19010207)
- Benjamin EJ, Munter P, Alonso A, Bittencourt MS, Callaway CW, Carson AP et al. Heart Disease and Stroke Statistics-2019 update: a report from the American Heart Association. *Circulation* 2019; **139**:e56–e528. doi: [10.1161/CIR.0b013e31820a55f5](https://doi.org/10.1161/CIR.0b013e31820a55f5)
- Heideneck PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. *Circulation* 2011; **123**:933–944. doi: [10.1161/CIR.0b013e31820a55f5](https://doi.org/10.1161/CIR.0b013e31820a55f5)
- Partridge L, Deelen J, Slagboom PE. Facing up to the global challenges of ageing. *Nature* 2018; **561**:45–56. doi: [10.1038/s41586-018-0457-8](https://doi.org/10.1038/s41586-018-0457-8)
- GBD 2019 Demographics Collaborators. Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. *Lancet* 2020; **396**:1160–1203. doi: [10.1016/s0140-6736\(20\)30977-6](https://doi.org/10.1016/s0140-6736(20)30977-6)
- GBD 2019 Stroke Collaborators. Global, regional, and national burden of diseases and injuries for adults 70 years and older: systematic analysis for the Global Burden of Disease 2019 Study. *BMJ* 2022; **376**:e068208. doi: [10.1136/bmj-2021-068208](https://doi.org/10.1136/bmj-2021-068208)
- GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet* 2020; **396**:1204–1222. doi: [10.1016/s0140-6736\(20\)30925-9](https://doi.org/10.1016/s0140-6736(20)30925-9)
- Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: update from the GBD 2019 study. *J Am Coll Cardiol* 2020; **76**:2982–3021. doi: [10.1016/j.jacc.2020.11.010](https://doi.org/10.1016/j.jacc.2020.11.010)
- Davinelli S, Corbi G, Righetti S, Sears B, Olarte HH, Grassi D et al. Cardioprotection by cocoa polyphenols and ω-3 fatty acids: a disease-prevention perspective on aging-associated cardiovascular risk. *J Med Food* 2018; **21**:1060–1069. doi: [10.1089/jmf.2018.0002](https://doi.org/10.1089/jmf.2018.0002)
- Khan MA, Hashim MJ, Mustafa H, Baniyas MY, Al Suwaidi S, AlKatheeri R et al. Global epidemiology of ischemic heart disease: results from the Global Burden of Disease study. *Cureus* 2020; **12**:e9349. doi: [10.7759/cureus.9349](https://doi.org/10.7759/cureus.9349)
- Amini M, Zayeri F, Salehi M. Trend analysis of cardiovascular disease mortality, incidence, and mortality-to-incidence ratio: results from Global Burden of Disease study 2017. *BMC Public Health* 2021; **21**:401. doi: [10.1186/s12889-021-10429-0](https://doi.org/10.1186/s12889-021-10429-0)
- de Bont J, Jaganathan S, Dahlquist M, Persson Å, Stafovoglia M, Ljungman P. Ambient air pollution and cardiovascular diseases: an umbrella review of systematic reviews and meta-analyses. *J Intern Med* 2022; **291**:779–800. doi: [10.1111/joim.13467](https://doi.org/10.1111/joim.13467)
- Kang Y, Tang H, Zhang L, Wang S, Wang X, Chen Z et al. Long-term temperature variability and the incidence of cardiovascular diseases: a large, representative cohort study in China. *Environ Pollut* 2021; **278**:116831. doi: [10.1016/j.envpol.2021.116831](https://doi.org/10.1016/j.envpol.2021.116831)
- United Nations Department of Economic and Social Affairs Population Division. World Population Prospects 2022. <https://population.un.org/wpp/> (26 May 2023).
- United Nations Population Division. World Population Ageing 2020 Highlights. <https://www.un.org/development/desa/pd/news/world-population-ageing-2020-highlights> (26 May 2023).
- Yang Q, Zhang Z, Gregg EW, Flanders WD, Merritt R, Hu FB. Added sugar intake and cardiovascular diseases mortality among US adults. *JAMA Intern. Med.* 2014; **174**:516–524. doi: [10.1001/jamainternmed.2013.13563](https://doi.org/10.1001/jamainternmed.2013.13563)
- Srouf B, Fezeu LK, Kesse-Guyot E, Allès B, Méjean C, Andrianasolo RM et al. Ultra-processed food intake and risk of cardiovascular disease: prospective cohort study (NutriNet-Santé). *BMJ* 2019; **365**:l1451. doi: [10.1136/bmj.l1451](https://doi.org/10.1136/bmj.l1451)
- Juul F, Vaidean G, Lin Y, Deierlein AL, Parekh N. Ultra-Processed Foods and Incident Cardiovascular Disease in the Framingham Offspring Study. *J Am Coll Cardiol* 2021; **77**:1520–1531. doi: [10.1016/j.jacc.2021.01.047](https://doi.org/10.1016/j.jacc.2021.01.047)

25. Mayosi BM, Lawn JE, van Niekerk A, Bradshaw D, Abdoor Karim SS, Coovadia HM. Health in South Africa: changes and challenges since 2009. *Lancet* 2012; **380**:2029–2043. doi: [10.1016/s0140-6736\(12\)61814-5](https://doi.org/10.1016/s0140-6736(12)61814-5)
26. Aringazina A, Kuandikov T, Arkhipov V. Burden of the cardiovascular diseases in Central Asia. *Cent Asian J Glob Health* 2018; **7**:321. doi: [10.5195/cajgh.2018.321](https://doi.org/10.5195/cajgh.2018.321)
27. Collins D, Laatikainen T, Farrington J. Implementing essential interventions for cardiovascular disease risk management in primary healthcare: lessons from Eastern Europe and Central Asia. *BMJ Glob Health* 2020; **5**:e002111. doi: [10.1136/bmigh-2019-002111](https://doi.org/10.1136/bmigh-2019-002111)
28. Murphy A, Johnson CO, Roth GA, Forouzanfar MH, Naghavi M, Ng M et al. Ischaemic heart disease in the former Soviet Union 1990–2015 according to the Global Burden of Disease 2015 Study. *Heart* 2018; **104**:58–66. doi: [10.1136/heartjnl-2016-311142](https://doi.org/10.1136/heartjnl-2016-311142)
29. Lui M, Safiri S, Mereke A, Davletov K, Mebonia N, Myrkassymova A et al. Burden of ischemic heart disease in Central Asian countries, 1990–2017. *Int J Cardiol Heart Vasc* 2021; **33**:100726. doi: [10.1016/j.ijcha.2021.100726](https://doi.org/10.1016/j.ijcha.2021.100726)
30. Wang JM, Kim BO, Bae JW, Oh DJ. Implementation of national health policy for the prevention and control of cardiovascular disease in South Korea: Regional-Local Cardio-Cerebrovascular Center and Nationwide Registry. *Korean Circ J* 2021; **51**:383–398. doi: [10.4070/kcj.2021.0001](https://doi.org/10.4070/kcj.2021.0001)
31. Sidney S, Quesenberry CP, Jr., Jaffe MG, Sorel M, Nguyen-Huynh MN, Kushi LH et al. Recent trends in cardiovascular mortality in the United States and public health goals. *JAMA Cardiol* 2016; **1**:594–599. doi: [10.1001/jamacardio.2016.1326](https://doi.org/10.1001/jamacardio.2016.1326)
32. Baptista EA, Kakinuma K, Queiroz BL. Association between cardiovascular mortality and economic development: a spatio-temporal study for Prefectures in Japan. *Int J Env Public Health* 2020; **17**:1311. doi: [10.3390/ijerph17041311](https://doi.org/10.3390/ijerph17041311)
33. Celermajer DS, Chow CK, Marjion E, Anstey NM, Woo KS. Cardiovascular disease in the developing world: prevalences, patterns, and the potential of early disease detection. *J Am Coll Cardiol* 2012; **60**:1207–1216. doi: [10.1016/j.jacc.2012.03.074](https://doi.org/10.1016/j.jacc.2012.03.074)
34. Husain MJ, Datta BK, Kostova D, Joseph KT, Asma S, Richter P et al. Access to cardiovascular disease and hypertension medicines in developing countries: an analysis of essential medicine lists, price, availability, and affordability. *J Am Heart Assoc* 2020; **9**:e015302. doi: [10.1161/jaha.119.015302](https://doi.org/10.1161/jaha.119.015302)
35. GBD 2019 Healthcare Access and Quality Collaborators. Assessing performance of the Healthcare Access and Quality Index, overall and by select age groups, for 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019. *Lancet Glob Health* 2022; **10**:e1715–e1e43. doi: [10.1016/s2214-109x\(22\)00429-6](https://doi.org/10.1016/s2214-109x(22)00429-6)
36. Chang ES, Kannoth S, Levy S, Wang SY, Lee JE, Levy BR. Global reach of ageism on older persons' health: a systematic review. *PLoS One* 2020; **15**:e0220857. doi: [10.1371/journal.pone.0220857](https://doi.org/10.1371/journal.pone.0220857)
37. Wang Z, Du A, Liu H, Wang Z, Hu J. Systematic analysis of the global, regional and national burden of cardiovascular diseases from 1990 to 2017. *J Epidemiol Glob Health* 2022; **12**:92–103. doi: [10.1007/s44197-021-00024-2](https://doi.org/10.1007/s44197-021-00024-2)
38. Nowbar AN, Gitto M, Howard JP, Francis DP, Al-Lamee R. Mortality from ischaemic heart disease. *Circ Cardiovasc Qual Outcomes* 2019; **12**:e005375. doi: [10.1161/circoutcomes.118.005375](https://doi.org/10.1161/circoutcomes.118.005375)
39. Forestier E, Selton-Suty C, Roubaud-Baudron C. Managing infective endocarditis in older patients: do we need a geriatrician? *Aging Clin Exp Res* 2021; **33**:719–722. doi: [10.1007/s40520-019-01400-6](https://doi.org/10.1007/s40520-019-01400-6)
40. Murdoch DR, Corey GR, Hoen B, Miró JM, Fowler VG, Jr., Bayer AS et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. *Arch Intern Med* 2009; **169**:463–473. doi: [10.1001/archinternmed.2008.603](https://doi.org/10.1001/archinternmed.2008.603)
41. Marcus GM, Alonso A, Peralta CA, Lettre G, Vittinghoff E, Lubitz SA et al. European ancestry as a risk factor for atrial fibrillation in African Americans. *Circulation* 2010; **122**:2009–2015. doi: [10.1161/circulationaha.110.958306](https://doi.org/10.1161/circulationaha.110.958306)
42. Alonso A, Agarwal SK, Soliman EZ, Ambrose M, Chamberlain AM, Prineas RJ et al. Incidence of atrial fibrillation in whites and African–Americans: the Atherosclerosis Risk in Communities (ARIC) study. *Am Heart J* 2009; **158**:111–117. doi: [10.1016/j.ahj.2009.05.010](https://doi.org/10.1016/j.ahj.2009.05.010)
43. Gillott RG, Willan K, Kain K, Sivananthan UM, Tayebjee MH. South Asian ethnicity is associated with a lower prevalence of atrial fibrillation despite greater prevalence of established risk factors: a population-based study in Bradford Metropolitan District. *Europace* 2017; **19**:356–363. doi: [10.1093/europace/euw010](https://doi.org/10.1093/europace/euw010)
44. Lau CP, Gbadebo TD, Connolly SJ, Van Gelder IC, Capucci A, Gold MR et al. Ethnic differences in atrial fibrillation identified using implanted cardiac devices. *J Cardiovasc Electrophysiol* 2013; **24**:381–387. doi: [10.1111/jce.12066](https://doi.org/10.1111/jce.12066)
45. Brunström M, Carlberg B. Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure levels: a systematic review and meta-analysis. *JAMA Intern Med* 2018; **178**:28–36. doi: [10.1001/jamainternmed.2017.6015](https://doi.org/10.1001/jamainternmed.2017.6015)
46. Weber MA, Bakris GL, Hester A, Weir MR, Hua TA, Zappe D et al. Systolic blood pressure and cardiovascular outcomes during treatment of hypertension. *Am J Med* 2013; **126**:501–508. doi: [10.1016/j.amjmed.2013.01.007](https://doi.org/10.1016/j.amjmed.2013.01.007)